Kurse werden geladen...
Prognose
Kaufen | 2 |
Halten | 0 |
Verkaufen | 0 |
Scoring-Modelle
Für dieses Unternehmen liegen uns bisher keine Scoring-Modelle vor.
News
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced a world-class panel to discuss the current state of pain therapy at their planned scientific symposium to be held during PAINWeek 2025. PAINWeek is the largest pain conference in the world where experts meet to share knowledge to enhance patient care.» Mehr auf accessnewswire.com
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today announced it was awarded the second $5.3 million installment of a $15 million, three-year grant from the National Institute on Drug Abuse (NIDA)1. This continued support will accelerate the clinical and non-clinical development of PF614-MPAR, a next-generation opioid designed to offer powerful pain relief while dramatically reducing the risk of overdose.» Mehr auf accessnewswire.com
Ensysce Biosciences Reports First Quarter 2025 Financial Results
Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and overdose, today reported financial and operational results for the first quarter ended March 31, 2025. Dr Lynn Kirkpatrick, Chief Executive Officer of Ensysce, commented, "We are pleased with the meaningful strides the Company has continued to make in the first quarter to deliver what we believe are the ‘Next Generation' opioid analgesics with both abuse and overdose protection.» Mehr auf accessnewswire.com
Unternehmenszahlen
(EUR) | März 2025 | |
---|---|---|
Umsatz | 1,22 Mio | 330,73% |
Bruttoeinkommen | 1,22 Mio | 378,40% |
Nettoeinkommen | −1,80 Mio | 37,70% |
EBITDA | −1,80 Mio | 3,71% |
Fundamentaldaten
Metrik | Wert |
---|---|
Marktkapitalisierung | 4,31 Mio€ |
Anzahl Aktien | 2,37 Mio |
52 Wochen-Hoch/Tief | 12,53€ - 1,38€ |
Dividenden | Nein |
Beta | 0,98 |
KGV (PE Ratio) | −0,44 |
KGWV (PEG Ratio) | −0,14 |
KBV (PB Ratio) | 0,98 |
KUV (PS Ratio) | 1,80 |
Unternehmensprofil
Name | Ensysce Biosciences Aktie |
CEO | Dr. D. Lynn Kirkpatrick Ph.D. |
Mitarbeiter | 7 |
Assets entdecken
Shareholder von Ensysce Biosciences Aktie investieren auch in folgende Assets